The European Medicines Agency's advisory committee has recommended against approving Eli Lilly's Alzheimer's treatment Kisunla, citing safety concerns related to brain swelling.
Asceneuron has halted its Phase I clinical trial of ASN90, a novel tau-targeting compound for Alzheimer's disease, adding to the growing list of setbacks in tau-based therapeutic approaches.
Eli Lilly's ceperognastat, an O-GlcNAcase inhibitor, slowed brain atrophy and tau accumulation in a Phase 2 trial for early symptomatic Alzheimer's disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.